Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0W9QG
|
||||
| Former ID |
DNCL001643
|
||||
| Drug Name |
SBI-087
|
||||
| Synonyms |
PF-05230895
|
||||
| Indication | Multiple scierosis; Rheumatoid arthritis [ICD9: 340, 710-719, 714; ICD10:G35, M05-M06] | Phase 2 | [1] | ||
| Company |
Emergent BioSolutions; Pfizer
|
||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01008852) Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis. U.S. National Institutes of Health. | ||||
| REF 2 | Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol. 2009 August; 157(2): 198-208. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.